← All trials
NCT04136353
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Jan 31, 2028
- Completion date
- Jul 31, 2028
- First posted
- —
- Last posted
- —
- Enrollment
- 1100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of SydneyLead sponsor
- BayerCollaborator
- Canadian Cancer Trials GroupCollaborator
- Australian and New Zealand Urogenital and Prostate Cancer Trials GroupCollaborator
- Cancer Trials IrelandCollaborator
- McGill UniversityStudy chair
- Harvard UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.